- Home
- GNLX vs PCF Comparison
GNLX vs PCF Comparison
Compare GNLX & PCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- PCF
- Stock Information
- Founded
- GNLX 2001
- PCF 1987
- Country
- GNLX United States
- PCF United States
- Employees
- GNLX N/A
- PCF N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- PCF Trusts Except Educational Religious and Charitable
- Sector
- GNLX Health Care
- PCF Finance
- Exchange
- GNLX Nasdaq
- PCF Nasdaq
- Market Cap
- GNLX 112.8M
- PCF 118.8M
- IPO Year
- GNLX 2023
- PCF N/A
- Fundamental
- Price
- GNLX $3.09
- PCF $6.44
- Analyst Decision
- GNLX Strong Buy
- PCF
- Analyst Count
- GNLX 4
- PCF 0
- Target Price
- GNLX $17.75
- PCF N/A
- AVG Volume (30 Days)
- GNLX 137.5K
- PCF 74.8K
- Earning Date
- GNLX 08-13-2025
- PCF 01-01-0001
- Dividend Yield
- GNLX N/A
- PCF 10.90%
- EPS Growth
- GNLX N/A
- PCF N/A
- EPS
- GNLX N/A
- PCF N/A
- Revenue
- GNLX N/A
- PCF N/A
- Revenue This Year
- GNLX N/A
- PCF N/A
- Revenue Next Year
- GNLX N/A
- PCF N/A
- P/E Ratio
- GNLX N/A
- PCF N/A
- Revenue Growth
- GNLX N/A
- PCF N/A
- 52 Week Low
- GNLX $1.60
- PCF $5.71
- 52 Week High
- GNLX $5.89
- PCF $6.96
- Technical
- Relative Strength Index (RSI)
- GNLX 56.10
- PCF 60.53
- Support Level
- GNLX $2.75
- PCF $6.31
- Resistance Level
- GNLX $3.17
- PCF $6.45
- Average True Range (ATR)
- GNLX 0.24
- PCF 0.05
- MACD
- GNLX -0.00
- PCF 0.01
- Stochastic Oscillator
- GNLX 56.94
- PCF 92.86
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective primarily by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.